White Paper

Assurance Of Clonality: A Key Regulatory Requirement For Biotherapeutics

Advanced Instruments Custom Image

Since the FDA’s approval of the first recombinant protein in 1986, the number of approved biopharmaceuticals has grown constantly over the years, reflecting their increasing relevance in modern medicine.1 By 2021, the FDA approved the 100th monoclonal antibody product2 together with nine other new biologic drugs, accounting for 16% of the total number of drugs approved that year.3 This 35-year pattern of steady growth in the biopharmaceutical market reflects how these drugs are one of the most effective clinical treatment modalities for a broad range of diseases; as a result, they are increasingly being used in almost all branches of medicine.4

The clonality of Master Cell Banks (MCBs) for production cell lines is a key requirement in biotherapeutics manufacturing. Learn how new devices help optimize the cloning process.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online